← The Wire
SYRENasdaq
Spyre Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1636282
Pioneering long-acting antibodies for inflammatory and rheumatic diseases
red 8-K · 90d
$7.02B
Market cap
$90.16
Last close
+2.6%
1D
-10.1%
5D
2.0M
Volume
Price · last 39 sessions+30.4%
May 4L $66.62 · H $100.32Jun 29
305
Total filings
Jun 15, 2026
Last filing
12/31
Fiscal year end
SC 13D/ASC 13D/AJun 23, 20268-KReg FD Disclosure · Company UpdateJun 15, 20268-KCompany UpdateJun 1, 20268-KExecutive Change · Shareholder VoteMay 29, 20268-KResults of OperationsMay 5, 202610-Q10-QMay 5, 2026SC 13D/ASC 13D/AApr 20, 20268-KMaterial AgreementApr 16, 2026424B5424B5Apr 16, 2026424B5424B5Apr 13, 20268-KResults of Operations · Company UpdateApr 13, 20268-KReg FD Disclosure · Company UpdateApr 13, 2026DEFA14ADEFA14AApr 10, 2026DEF 14ADEF 14AApr 10, 20268-KResults of OperationsFeb 19, 202610-K10-KFeb 19, 20268-KReg FD DisclosureJan 12, 20268-KResults of Operations · Reg FD DisclosureNov 4, 202510-Q10-QNov 4, 20258-KMaterial AgreementOct 15, 2025424B5424B5Oct 14, 2025424B5424B5Oct 14, 20258-KResults of OperationsOct 14, 20258-KResults of OperationsAug 5, 202510-Q10-QAug 5, 20258-KReg FD Disclosure · Company UpdateJun 17, 20258-KShareholder VoteJun 2, 20258-KResults of OperationsMay 8, 202510-Q10-QMay 8, 2025DEFA14ADEFA14AApr 14, 2025DEF 14ADEF 14AApr 14, 20258-KAuditor ChangeMar 6, 20258-KResults of OperationsFeb 27, 202510-K10-KFeb 27, 20258-KResults of Operations · Company UpdateJan 13, 20258-KMaterial AgreementNov 19, 2024424B5424B3Nov 19, 2024424B5424B5Nov 18, 202410-Q/A10-Q/ANov 18, 202410-Q/A10-Q/ANov 18, 202410-Q/A10-Q/ANov 18, 202410-K/A10-KNov 18, 20248-KRestatement · Company UpdateNov 18, 20248-KReg FD Disclosure · Company UpdateNov 12, 2024SC 13GSC 13GNov 8, 20248-KResults of OperationsNov 7, 202410-Q10-QNov 7, 2024SC 13GSCHEDULE 13GOct 23, 2024SC 13GSC 13GOct 22, 20248-KMaterial Agreement · Reg FD DisclosureOct 15, 20248-K/ACompany UpdateAug 8, 20248-KResults of OperationsAug 7, 202410-Q10-QAug 7, 20248-KReg FD DisclosureMay 30, 20248-KExecutive Change · Material AgreementMay 15, 20248-KResults of OperationsMay 9, 202410-Q10-QMay 9, 20248-KEquity IssuanceApr 25, 2024S-1S-1Apr 19, 2024DEF 14ADEF 14AApr 1, 2024S-1/AS-1/AMar 27, 20248-KMaterial Agreement · Equity IssuanceMar 18, 2024S-1/AS-1/AMar 14, 2024S-1/AS-1/AMar 1, 202410-K/A10-K/AMar 1, 20248-KResults of OperationsFeb 29, 202410-K10-KFeb 29, 2024SC 13GSPYRE THERAPEUTICS, INC.Feb 14, 2024SC 13GSPYRE THERAPEUTICS, INC.Feb 14, 2024SC 13GSC 13GFeb 9, 20248-KExecutive Change · Material AgreementFeb 5, 2024S-1/AS-1/AFeb 5, 20248-KDelisting NoticeJan 18, 2024S-1S-1Dec 22, 2023SC 13GSC 13GDec 13, 20238-KMaterial Agreement · Equity IssuanceDec 8, 2023SC 13GSC 13GDec 1, 20238-KExecutive Change · Bylaw AmendmentNov 28, 20238-KBylaw Amendment · Shareholder VoteNov 24, 2023S-1/AS-1/ANov 15, 2023
Insider Activity
In the 90 days to Mar 3, 2026: 2 sold $1.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 3, 2026 | Burrows Scott LChief Financial Officer | Sell | 2,300 | $40.56 | $93K |
| Mar 3, 2026 | Burrows Scott LChief Financial Officer | Sell | 200 | $41.66 | $8K |
| Mar 2, 2026 | Turtle CameronChief Executive Officer | Sell | 9,100 | $42.49 | $387K |
| Mar 2, 2026 | Turtle CameronChief Executive Officer | Sell | 5,900 | $41.73 | $246K |
| Feb 2, 2026 | Turtle CameronChief Executive Officer | Sell | 14,043 | $32.87 | $462K |
| Feb 2, 2026 | Turtle CameronChief Executive Officer | Sell | 957 | $31.82 | $30K |
| Jan 2, 2026 | Turtle CameronChief Executive Officer | Sell | 12,709 | $30.47 | $387K |
| Jan 2, 2026 | Turtle CameronChief Executive Officer | Sell | 2,191 | $31.79 | $70K |
| Jan 2, 2026 | Turtle CameronChief Executive Officer | Sell | 100 | $32.39 | $3K |
| Dec 1, 2025 | Turtle CameronChief Executive Officer | Sell | 10,995 | $28.73 | $316K |
| Dec 1, 2025 | Turtle CameronChief Executive Officer | Sell | 4,005 | $29.83 | $119K |
| Nov 3, 2025 | Turtle CameronChief Executive Officer | Sell | 28,155 | $23.13 | $651K |
| Nov 3, 2025 | Turtle CameronChief Executive Officer | Sell | 16,845 | $23.66 | $399K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance